Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic (Q36275522)

13 August 2017

1 reference

title

Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic (English)

1 reference

13 August 2017

1 reference

Hideaki Miyake

1

1 reference

PubMed ID

16201973

13 August 2017

Isao Hara

series ordinal

2

1 reference

PubMed ID

16201973

13 August 2017

Martin E Gleave

series ordinal

3

1 reference

13 August 2017

1 September 2005

1 reference

International Journal of Urology

13 August 2017

1 reference

13 August 2017

12

1 reference

13 August 2017

9

1 reference

13 August 2017

785-794

1 reference

Management of hormone refractory prostate cancer: current standards and future prospects

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin: physiologic and pathophysiologic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Potential roles of antisense technology in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Antisense oligonucleotides: promise and reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Overexpression of clusterin in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Stress-induced transcription of the clusterin/apoJ gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Modulation of different clusterin isoforms in human colon tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Synthesis and functional analyses of nuclear clusterin, a cell death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Repression of IR-Inducible Clusterin Expression by the p53 Tumor Suppressor Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Gene inhibition using antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Insulin-like growth factors and their binding proteins: biological actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

X-linked IAP is a direct inhibitor of cell-death proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2005.01173.X

10.1111/J.1442-2042.2005.01173.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16201973